Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;39(11):2091-2097.
doi: 10.1002/mds.29937. Epub 2024 Jul 25.

Prokineticin-2 Is Highly Expressed in Colonic Mucosa of Early Parkinson's Disease Patients

Affiliations

Prokineticin-2 Is Highly Expressed in Colonic Mucosa of Early Parkinson's Disease Patients

Gabriele Bellini et al. Mov Disord. 2024 Nov.

Abstract

Background: Elevated levels of prokineticin-2 (PK2), regarded as a protein involved in modulating immune/inflammatory responses, have been detected in the substantia nigra, serum, and olfactory neurons of Parkinson's disease (PD) patients. Of note, emerging evidence suggests that gut alterations, including dysbiosis and enteric inflammation, play a role in PD via the gut-brain axis.

Objectives: Our goal was to investigate the expression of PK2 in colonic biopsies of PD patients.

Methods: Mucosal biopsies from the descending colon were obtained in 11 PD patients and five asymptomatic subjects. Biopsy samples were processed for PK2 immunofluorescence and western blot.

Results: We revealed an increased PK2 expression in colonic mucosa from PD patients in the early stages compared to controls. In addition, we found that PK2 was expressed by activated enteric glial cells and macrophages.

Conclusions: PK2 is highly expressed within neurogenic/inflammatory cells of colonic mucosa from early PD patients, suggesting a potential role of PK2 in gut inflammation, especially in the early stages of PD. © 2024 International Parkinson and Movement Disorder Society.

Keywords: gutgut‐brainneuroinflammationParkinson's diseaseprokineticin‐2.

PubMed Disclaimer

References

    1. Muñoz‐Delgado L, Labrador‐Espinosa MÁ, Macías‐García D, et al. Peripheral inflammation is associated with dopaminergic degeneration in Parkinson's disease. Mov Disord 2023;38(5):755–763.
    1. Lattanzi R, Severini C, Maftei D, Saso L, Badiani A. The role of prokineticin 2 in oxidative stress and in neuropathological processes. Front Pharmacol 2021;12:1–8.
    1. Lattanzi R, Maftei D, Petrella C, et al. Involvement of the chemokine prokineticin‐2 (PROK2) in alzheimer's disease: from animal models to the human pathology. Cells 2019;8:1430.
    1. Gordon R, Neal ML, Luo J, et al. Prokineticin‐2 upregulation during neuronal injury mediates a compensatory protective response against dopaminergic neuronal degeneration. Nat Commun 2016;7:1–18. https://doi.org/10.1038/ncomms12932
    1. Schirinzi T, Maftei D, Passali FM, et al. Olfactory neuron Prokineticin‐2 as a potential target in Parkinson's disease. Ann Neurol 2023;93:196–204.

LinkOut - more resources